Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 60, Issue 1, 2011, Pages 52-56

  Cuthbertson, Joy ^a   Patterson, Steven ^b   O'Harte, Finbarr P ^b   Bell, Patrick M ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO;

ADD ON THERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; DIABETES MELLITUS; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN;

EID: 78649908592     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.01.001     Document Type: Article

References (30)

1. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., and Sherwin R. Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy Diabetes Care 32 2009 193 203
2. Nauck M.A., Vilsboll T., Gallwitz B., Garber A., and Madsbad S. Incretin-based therapies. Viewpoints on a way to consensus Diabetes Care 32 Suppl 2 2009 S223 S231
3. Drucker D.J. Glucagon-like peptides: regulators of cell proliferation, differentiation and apoptosis Mol Endocrinol 17 2003 161 171
4. Farilla A., Bulotta A., Hirshberg B., Calzi S.L., Khoury N., and Noushmehr H. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets Endocrinology 12 2003 5149 5158
5. Edwards C.M., Todd J.F., Ghatei M.A., and Bloom S.R. Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects Clin Sci 95 1998 719 724
6. Todd J.F., Edwards C.M., Ghatei M.A., Mather H.M., and Bloom S.R. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes Clin Sci 95 1998 325 329
7. Rachman J., Barrow B.A., Levy J.C., and Turner R.C. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM Diabetologia 40 1997 205 211
8. Zander M., Madsbad S., Madsen J.L., and Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 359 2002 824 830
9. Deacon C.F., Pridal L., Klarskov L., Olesen M., and Holst J.J. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anaesthetized pig Am J Physiol 271 1996 E458 E464
10. Mentlein R., Gallwitz B., and Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum Eur J Biochem 214 1993 829 835
11. World Health Organization Definition, diagnosis and classification of diabetes mellitus. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus 1999 World Health Organization Geneva 1 59
12. Knop F., Vilsbøll T., Larsen S., Madsbad M., Holst J., and Krarup T. No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis Diabetes Care 26 2003 2581 2587
13. Stevens J.F. Determination of glucose by an automatic analyser Clin Chim Acta 32 1971 199 201
14. Lindsay J.R., Duffy N.A., McKillop A.M., Ardill J., O'Harte F.P.M., and Flatt P.R. Inhibition of dipeptidyl peptidase IV (DPP-IV) activity by oral metformin in type 2 diabetes Diabet Med 22 2005 654 657
15. McKillop A.M., Duffy N.A., Lindsay J.R., O'Harte F.P.M., Bell P.M., and Flatt P.R. Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects Diabetes Res Clin Pract 79 2008 79 85
16. Green B., Duffy N.A., Irwin N., Gault V.A., O'Harte F.P.M., and Flatt P.R. Inhibition of dipeptidyl peptidase IV (DPPIV) activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1 (GLP-1) Eur J Pharmacol 547 2006 192 199
17. Ritzel R., Vrskov C., Holst J.J., and Nauck M.A. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1(7-36)amide after subcutaneous injection in healthy volunteers. Dose-response relationships Diabetologia 38 1995 720 725
18. Larsson H., Holst J.J., and Ahren B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans Acta Physiol Scand 160 1997 413 422
19. Dardevet D., Moore M.C., Neal D., DiCostanzo C.A., Snead W., and Cherrington A.D. Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region Am J Physiol Endocrinol Metab 287 2004 E75 E81
20. Ma X., Zhang Y., Gromada J., Sewing S., Berggren P.O., and Buschard K. Glucagon stimulates exocytosis in mouse and rat pancreatic alpha-cells by binding to glucagon receptors Mol Endocrinol 9 2005 198 212
21. Creutzfeldt W., Orskov C., Kleine N., Holst J.J., Willms B., and Nauck M.A. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1(7-36) amide in type 1 patients Diabetes Care 19 1996 580 586
22. Toft-Nielsen M.B., Madsbad S., and Holst J.J. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes J Clin Endocrinol Metab 86 2001 3853 3860
23. Luque M.A., González N., Márquez L., Acitores A., Redondo A., and Morales M. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes J Endocrinol 173 2002 465 473
24. Mentlein R. Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides Regul Pept 85 1999 9 24
25. Ahren B., Holst J., Mårtensson H., and Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice Eur J Pharmacol 404 2000 239 445
26. Winzell M.S., and Ahrén B.O. Role of VIP and PACAP in islet function Peptides 28 2007 1805 1813
27. Herman G.A., Stevens C., Van Dyck K., Bergman A., Yi B., and De Smet M. Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects Clin Pharmacol Ther 78 2005 675 688
28. Amori R.E., Lau J., and Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 298 2007 194 206
29. Aschner P., Kipnes M.S., and Lunceford J.K. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 29 2006 2632 2637
30. Inzucchi S.E., Maggs D.G., Spollett G.R., Page S.L., Rife F.S., and Walton V. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus N Engl J Med 338 1998 867 872